SCHEMBL95824

SCHEMBL95824

CCCCOc1ccc(CC)cc1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.63
ALDH1A1 P00352 1/20 0.63
LMNA P02545 1/20 0.63
MAPT P10636 1/20 0.63
HPGD P15428 1/20 0.63
LTA4H P09960 4/20 0.57
NR5A1 Q13285 1/20 0.55
CYP2D6 P10635 2/20 0.55
KDM4E B2RXH2 1/20 0.55
CYP1A2 P05177 1/20 0.55
PDE4A P27815 1/20 0.55
HIF1A Q16665 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
TSHR P16473 1/20 0.55
HRH3 Q9Y5N1 1/20 0.54
CYP3A4 P08684 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8348497 0.96 NR5A1 (0.62) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL12513541 0.94 CYP2D6 (0.63) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL9072656 0.94 NR5A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL11864814 0.94 NR5A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL12302872 0.94 NR5A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL23350372 0.94 NR5A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL14608534 0.94 NR5A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL13242054 0.94 NR5A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL11339167 0.94 NR5A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL5526720 0.94 NR5A1 (0.66) SMN1; SMN2ALDH1A1LMNAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016578-A1 METHODS FOR ADDITIVELY MANUFACTURING MEDICAL DEVICES USING BIOGLASS FIBER REINFORCED POLYMERS TU WIEN (AT) 2024-01-18 US disclosed
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2024-01-18 US disclosed
US-20240016578-A1 METHODS FOR ADDITIVELY MANUFACTURING MEDICAL DEVICES USING BIOGLASS FIBER REINFORCED POLYMERS TU WIEN (AT) 2024-01-18 US disclosed
US-20230210635-A1 CURABLE COMPOSITION FOR USE IN A HIGH TEMPERATURE LITHOGRAPHY-BASED PHOTOPOLYMERIZATION PROCESS AND METHOD OF PRODUCING CROSSLINKED POLYMERS THEREFROM ALIGN TECHNOLOGY INC (US) 2023-07-06 US disclosed
US-20230210635-A1 CURABLE COMPOSITION FOR USE IN A HIGH TEMPERATURE LITHOGRAPHY-BASED PHOTOPOLYMERIZATION PROCESS AND METHOD OF PRODUCING CROSSLINKED POLYMERS THEREFROM ALIGN TECHNOLOGY INC (US) 2023-07-06 US disclosed
EP-3564282-B1 CURABLE COMPOSITION FOR USE IN A HIGH TEMPERATURE PHOTOPOLYMERISATION METHOD ON A LITHOGRAPHY BASIS AND PROCESS FOR THE PREPARATION OF CROSS-LINKED POLYMERS THEREFROM ALIGN TECHNOLOGY INC (US) 2023-06-07 EP disclosed
CN-112979917-B Isocyanate composition, method for producing isocyanate composition, and method for producing isocyanate polymer 旭化成株式会社 2023-04-25 CN disclosed
US-11542362-B2 Curable composition for use in a high temperature lithography-based photopolymerization process and method of producing crosslinked polymers therefrom ALIGN TECHNOLOGY, INC. (US) 2023-01-03 US disclosed
CN-109790269-B Isocyanate composition, method for producing isocyanate composition, and method for producing isocyanate polymer 旭化成株式会社 2022-06-14 CN disclosed
WO-2022120207-A1 BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX UNIVERSITY OF MARYLAND, BALTIMORE (US) 2022-06-09 WO disclosed
US-7169818-B2 Lysophosphatidic acid receptor agonists and antagonists UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2007-01-30 US disclosed
WO-2004002483-A1 SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER’S DISEASE ACTELION PHARMACEUTICALS LTD (CH) 2004-01-08 WO disclosed
WO-2003007954-A2 SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS PHARMACIA CORPORATION (US) 2003-01-30 WO disclosed
CN-1032435-A The phenyl trifluoromethyl ethers that replaces MERCK PATENT GMBH (DE) 1989-04-19 CN disclosed
US-4459186-A Electrochemical oxidation of alkyl aromatic compounds UOP INC. (US) 1984-07-10 US disclosed
US-4249027-A Process for the preparation of 5-substituted resorcinols and related intermediates CIBA-GEIGY CORPORATION (US) 1981-02-03 US disclosed
US-4212711-A Electrochemical oxidation of alkyl aromatic compounds UOP INC. (US) 1980-07-15 US disclosed
US-4212710-A Electrochemical oxidation of alkyl aromatic compounds UOP INC. (US) 1980-07-15 US disclosed
US-4148696-A Electrochemical oxidation of activated alkyl aromatic compounds UOP INC. (US) 1979-04-10 US disclosed
US-4020098-A Process for the preparation of 5-substituted resorcinols and related intermediates CIBA-GEIGY CORPORATION (US) 1977-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS MAOA, DRD2, MAOB SMN1; SMN2 2102/4885ALDH1A1 1214/4885LMNA 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.